Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

David Chiou

Internal Medicine Round Lake Beach, IL Medical Doctor

NPI 1093779084 CMS profile 50031

1740 N Circuit Dr, Round Lake Beach, IL 60073

Open in the dashboard

General payments

$5,696

316 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, David Chiou of Round Lake Beach, IL is reported in the CMS Open Payments database as having received $5,696 across 316 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 90th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $220 8
2024 General $361 16
2023 General $418 21
2022 General $829 49
2021 General $1,430 82
2020 General $1,513 79
2019 General $926 61

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • David Chiou
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to David Chiou were reported at $220. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year David Chiou Internal Medicine median Middle half National median
2019 $926 $159 $48–$570 $163
2020 $1,513 $119 $33–$402 $114
2021 $1,430 $135 $37–$521 $132
2022 $829 $141 $42–$496 $149
2023 $418 $149 $45–$519 $160
2024 $361 $154 $47–$537 $164
2025 $220 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Boehringer Ingelheim Pharmaceuticals, Inc. $805 43 payments
  2. Novo Nordisk Inc $744 36 payments
  3. AbbVie, Inc. $598 41 payments
  4. Janssen Pharmaceuticals, Inc $501 27 payments
  5. Pfizer Inc. $316 11 payments
  6. GlaxoSmithKline, LLC. $265 15 payments
  7. Amarin Pharma Inc. $243 12 payments
  8. Amgen Inc. $243 15 payments
  9. Allergan Inc. $174 15 payments
  10. Merck Sharp & Dohme Corporation $169 10 payments
  11. Other $1,638 91 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $5,667 314 payments
  2. Education $30 2 payments
Products named General payments · program years 2019–2025
  1. JARDIANCE $546 30 payments
  2. Ozempic $499 25 payments
  3. RYBELSUS $426 21 payments
  4. SPIRIVA RESPIMAT $342 17 payments
  5. UBRELVY $323 22 payments
  6. ELIQUIS $316 11 payments
  7. STIOLTO RESPIMAT $298 15 payments
  8. SPRAVATO $266 14 payments
  9. INVEGA SUSTENNA $254 14 payments
  10. Vascepa $243 12 payments
  11. Other $5,093 293 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 159 drugs

Part D claims

8,457

Median for Internal Medicine: 777

Drug cost

$472,949

Median for Internal Medicine: $73,373

Branded share of claims

18.9%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 228 $85,532
Januvia Sitagliptin Phosphate Brand 122 $60,191
Glatiramer Acetate Generic 25 $33,262
Jardiance Empagliflozin Brand 16 $18,799
Breztri Aerosphere Budesonide/Glycopyr/Formoterol Brand 17 $17,024
Xarelto Rivaroxaban Brand 29 $16,576
Entresto Sacubitril/Valsartan Brand 11 $14,288
Ozempic Semaglutide Brand 13 $13,265
Breo Ellipta Fluticasone/Vilanterol Brand 30 $13,194
Potassium Chloride Generic 142 $8,066

The 10 drugs with the highest cost, of 159 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 38 billing codes

Paid by Medicare

$257,958

Of which drugs: $555

Medicare patients

292

Average age 74

Services billed

2,893

156 women, 136 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 69%
Diabetes 42%
Depression 33%
Ischemic heart disease 31%
Chronic kidney disease 31%
Heart failure 27%
Atrial fibrillation 27%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Vaccine for influenza for administration into muscle, 0.5 ml dosage 90656 Office 13 13 $285

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 12 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
IBSRELA
  • Ardelyx, Inc. $58
$58 — —
RYBELSUS
  • Novo Nordisk Inc $34
$34 — —
Ozempic
  • Novo Nordisk Inc $34
$34 13 —
REXULTI
  • Otsuka America Pharmaceutical, Inc. $29
$29 — —
SPRAVATO
  • Janssen Pharmaceuticals, Inc $25
$25 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 12 in the dashboard with a free account

Records

316 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Illinois

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record